(Q34001596)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

review article

1 reference

title

Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Siegfried Kasper

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Hans-Ulrich Wittchen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

J A den Boer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

L L Judd

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

J E Kelsey

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M Lader

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Y Lecrubier

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

J P Lepine

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

R B Lydiard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

J Mendlewicz

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

S A Montgomery

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

G Racagni

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M B Stein

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 October 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

Journal of Affective Disorders

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

61-74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

Social phobia: a comparative clinical study

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Brief Report: Discriminating Between Problems in Living: An Examination of Measures of Depression, Loneliness, Shyness, and Social Anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

The Zurich Study--a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. IV. Recurrent and nonrecurrent brief depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Physiological, cognitive and behavioral aspects of social anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Psychiatric correlates of behavioral inhibition in young children of parents with and without psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Lifetime prevalence of psychiatric disorders in Edmonton

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Gender differences in phobias: Results of the ECA community survey

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Age at onset of selected mental disorders in five community populations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

The 35% CO2 challenge test in patients with social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

An investigation into the psychobiology of social phobia: personality domains and serotonergic function.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

The assessment and treatment of performance anxiety in musicians

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

The Boundary of Social Phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Social phobia subtypes in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Classification and epidemiology of social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Citalopram in the treatment of social phobia: a report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Social phobia. Review of a neglected anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Specificity of lactate infusions in social phobia versus panic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

The role of drug therapy in social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Alcohol Dependence and Phobias: Clinical Description and Relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Moclobemide in social phobia: a controlled dose-response trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Moclobemide in the treatment of social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Social phobia and clonazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Epinephrine infusions in patients with social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Diagnostic and substance specificity of carbon-dioxide-induced panic.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Magnetic resonance imaging in social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

The epidemiology of anxiety disorders: the Epidemiologic Catchment Area (ECA) experience

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Comorbidity of parental anxiety disorders as risk for childhood-onset anxiety in inhibited children

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Syndrome comorbidity in patients diagnosed with a DSM-III-R anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Social phobia. Comorbidity and morbidity in an epidemiologic sample

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Placebo-controlled trial of moclobemide in social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Delineating social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Comparison of patients with panic disorder and social phobia and normal control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

[3H]paroxetine binding to platelets of patients with social phobia: comparison to patients with panic disorder and healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Plasma neuropeptide Y in anxiety disorders: findings in panic disorder and social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

The hypothalamic-pituitary-thyroid axis in social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Dopamine reuptake site densities in patients with social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Pharmacotherapy of Social Phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Social phobia: long-term treatment outcome and prediction of response--a moclobemide study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Social phobia in general health care: an unrecognised undertreated disabling disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Christchurch Psychiatric Epidemiology Study, Part I: Methodology and lifetime prevalence for specific psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

The impact of social phobia on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Reliability and procedural validity of UM-CIDI DSM-III-R phobic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Prevalence of mental disorders and psychosocial impairments in adolescents and young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

Situational determinants of social anxiety in clinic and nonclinic samples: physiological and cognitive correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2899%2900140-8

7 January 2021

10.1016/S0165-0327(99)00140-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10940449%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference